Table 2.
Number of residents using drugs with PGx actionable guidelines.
| PGx Target | Total Number of Residents. (%) | AGE Groups (Year) Number (%) |
||
|---|---|---|---|---|
| 65–74 | 75–84 | 85–98 | ||
| PGx-drugs (all) | 119 | 20 | 46 | 53 |
| CYP2C19 drugs | 87 (73.1) | 15 (75.0) | 38 (82.6) | 35 (66.0) |
| 1 drug | 50 (42.0) | 8 (40.0) | 21 (45.7) | 21 (39.6) |
| 2 drugs | 30 (25.2) | 6 (30.0) | 11 (23.9) | 13 (24.5) |
| 3 drugs | 6 (5.0) | 1 (5.0) | 5 (10.9) | 0 (-) |
| 4 drugs | 1 (0.8) | 0 (-) | 0 (-) | 1 (1.9) |
| CYP2D6 drugs | 47 (39.5) | 6 (30.8) | 14 (30.4) | 27 (50.9) |
| 1 drug | 40 (33.6) | 4 (20.0) | 12 (26.1) | 24 (45.3) |
| 2 drugs | 7 (5.9) | 2 (10.0) | 2 (4.3) | 3 (5.7) |
| CYP2C9 drug | 3 (2.5) | 0 (0) | 1 (2.2) | 2 (3.8) |
| SLCO1B1 drug | 42 (35.2) | 9 (45.0) | 23 (50.0) | 10 (18.9) |
The percentage shown in brackets are calculated relative to “PGx-drugs all” for the different age group columns. No statistical differences among the groups were found (Chi-squared test).